Top Companies in the Cell and Gene Therapy Isolator Market
- SKAN AG
- Getinge AB
- Azbil Telstar
- Comecer (ATS Automation)
- Germfree Laboratories
- Esco Aster
- MBRAUN
- Tema Sinergie
- BioSpherix
- Fedegari Group
- Vanrx (Cytiva)
- WABO Isolator Systems
- Tofflon Science and Technology
- Nuaire Inc.
- Lancer (Getinge Group)
- Hosokawa Micron Ltd.
- Skanfog Technologies
- Extract Technology (Wabash)
- Carlo Erba Group
- ITECO Engineering
Market Growth
The global cell and gene therapy isolator market size is calculated at USD 1.35 billion in 2024, grew to USD 1.52 billion in 2025, and is projected to reach around USD 4.47 billion by 2034. The market is expanding at a CAGR of 12.54% between 2025 and 2034.
Cell and Gene Therapy Isolator Market Trends
Increasing Collaboration: In April 2024, Multiply Labs announced a strategic partnership with GenScript Biotech Corporation to introduce automation in the cell isolation phase of cell therapy manufacturing. The collaboration was made to combine Multiply Labs’ cell therapy robotic cluster and GenScript’s GMP-grade CytoSinct 1000 cell isolation solution, enabling the isolation of 120 × 10^9 cells per hour.
Venture Capital Investment: In June 2025, Akadeum Life Sciences announced that it raised $20 million in funding. The funding was raised to scale commercial operations and support customers entering clinical trials. The company has developed a GMP-compliant product suite to advance next-generation cell therapies.
Value Chain Analysis of the Cell and Gene Therapy Isolator Market
R&D
The research and development activities for CGT isolators refer to the design, testing, and improvement of isolators for the development and manufacturing of CGTs. Researchers focus on providing maximum protection for the operator during the manipulation operations.
Key Players: Comecer, Thermo Fisher Scientific, and Tailin
Regulatory Approvals
CGT isolators must comply with stringent current good manufacturing practices (cGMP) regulations to manufacture CGTs.
Patient Support & Services
CGT isolators prevent contamination and provide an aseptic environment for CGT products. This provides patients with high-quality and high-purity CGTs.
Latest Announcement by Industry Leaders
Jon Ellis, CEO of Trenchant BioSystems, commented that the use of cell and gene therapy manufacturing practices to deliver therapies to large-scale patient populations in an affordable manner is possible. The company has developed a manufacturing platform to reduce manufacturing timelines to 2.5 days and costs by over 80%. It has selected Autolomous’ autoloMate as the most advanced CGT-specific digital platform to integrate digitalization.
Recent Developments in the Cell and Gene Therapy Isolator Market
- In December 2024, Thermo Fisher Scientific, Inc. launched the Gibco™ CTS™ Detachable Dynabeads™ CD4 and CTS Detachable Dynabeads CD8. The platform represents a new generation of cell therapy isolation and activation products and prioritizes cell quality.
- In September 2024, Lifecore Biomedical, Inc. announced the installation of a high-speed, multi-purpose 5-head isolator filler to offer existing and future customers the speed and aseptic isolation benefits. The installation of the equipment will improve the company’s leadership position and diversify its customer base.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking